P1.01-023 ALK-Positive NSCLC: A TMH Experience

ALK and NSCLC: Targeted therapy with ALK inhibitors

For many years treatment for advanced or metastatic non-small cell lung cancer (NSCLC) has employed chemotherapy regimens for patient care, with limited effect. Five-year survival rates for these patients are not encouraging. However, for a subgroup of these patients, there have been radical changes over recent years. Our understanding of the basic pathology behind NSCLC at the molecular level ...

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.

BACKGROUND Crizotinib is approved to treat advanced ALK-positive non-small-cell lung cancer (NSCLC), but most patients ultimately develop progressive disease (PD). We investigated whether continuing ALK inhibition with crizotinib beyond PD (CBPD) is clinically beneficial and attempted to identify clinicopathologic characteristics associated with patients who experience clinical benefit. PATIE...

The continuum of care for ALK-positive NSCLC: from diagnosis to new treatment options - an overview.

An ALK-positive NSCLC patient with the G1202R mutation detected by next-generation sequencing

Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors are currently essential drugs in the treatment of the subset of patients with non-small-cell lung cancer (NSCLC) showing ALK rearrangement. Notwithstanding, even the response to ALK inhibitors is usually not sustained in these patients, because of the occurrence of secondary mutations in ALK, MET amplification, or other unknown alterat...

Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.

PURPOSE Anaplastic lymphoma kinase (ALK) rearrangements are important therapeutic targets in non-small cell lung cancer (NSCLC) that confer sensitivity to the ALK inhibitors crizotinib and ceritinib. To determine the outcome of sequential treatment with crizotinb and ceritinib, we retrospectively evaluated a cohort of ALK-positive patients treated with both agents. EXPERIMENTAL DESIGN We iden...